Three Years on a Drug the Guideline No Longer Recommends: Antacid Therapy in Stable IPF
A woman has taken a reflux drug for three years for a diagnosis she has never actually had — the disagreement is whether the guideline that once recommended it, then reversed itself, is reason enough to stop.
F.O., a 69-year-old woman, spends most Tuesday afternoons picking her granddaughter up from school and staying for dinner, a standing arrangement that has outlasted both of her knee replacements and, so far, her IPF. She has been on omeprazole since her diagnosis three years ago — started, her chart notes, simply because her first pulmonologist believed at the time that treating silent reflux might slow her lung disease. She has never once reported heartburn, regurgitation, or any symptom suggesting gastroesophageal reflux disease, and no formal reflux testing was ever performed; the omeprazole was started on the reflux-and-fibrosis theory alone, not on a diagnosis she actually carries. Her IPF itself has been reasonably stable on nintedanib, with FVC holding around 74% predicted for the past year, and she has tolerated both medications without any reported side effect. A new pulmonologist inheriting her care noticed the omeprazole while reviewing her chart and is now the first person to actually ask whether it should still be there.
The theory behind starting it — that silent microaspiration of refluxed gastric contents contributes to fibrotic injury — drove a 2015 guideline that conditionally recommended antacid therapy for IPF on exactly that reasoning. The 2022 update reversed that recommendation after Khor and colleagues' systematic review of nineteen studies found only two were actual randomized trials, the rest observational, and judged the overall evidence too low-quality to support continuing to recommend a drug for the purpose of improving respiratory outcomes; the updated guideline now conditionally recommends against it. The detail that matters most for F.O. sits in that review's own methods section. The committee set out to ask about patients with IPF and confirmed reflux, and had to widen the search because no study anywhere had stratified IPF patients by whether reflux was actually documented. Every trial and cohort in that literature enrolled IPF patients regardless. F.O. has never been tested, so she was never inside the population the 2015 recommendation was built on, and she is not inside the population the 2022 reversal was built on either. Not every voice in the field accepted the reversal quietly — a subsequent published rebuttal argued the two real randomized trials were being drowned out by a flood of weaker observational studies rather than fairly weighed on their own. For F.O., though, the sharper question sitting underneath all of that is simpler: she was never treated for reflux she has, she was treated for a lung-outcome theory that has since been reversed.
What the pill was actually for
Stop the omeprazole. The 2022 ATS/ERS/JRS/ALAT guideline reversed its own prior recommendation after Khor and colleagues' systematic review found only two of nineteen studies were randomized trials, and judged the overall evidence too weak to support antacid therapy for respiratory benefit. She's never had a reflux diagnosis to begin with, so there's no remaining reason for the drug.
You're right that the review behind the reversal is real and not fringe. But Crowley, Wilson, and Thickett published a direct rebuttal arguing the two genuine randomized trials were being drowned out by weaker observational data rather than fairly weighed, and she's tolerated this medication for three years without any problem. I'd want more certainty before disrupting something stable.
Three years without a problem tells us the drug hasn't visibly harmed her — it doesn't tell us it's been doing anything, which is the actual question on the table.
The guideline itself separates two questions we're conflating: treating GERD for its own sake, and treating it specifically to improve respiratory outcomes. She has no GERD diagnosis, so the first question was never in play; the second is what the 2022 review found unsupported. Either way, there was never a genuine indication for this drug in the first place — that's true regardless of how the RCT-versus-observational disagreement ultimately resolves.
Agreed: discontinue omeprazole, with the reasoning documented clearly in her chart so a future clinician doesn't restart it reflexively; if she ever develops actual reflux symptoms, that would be treated on its own separate indication.
Not agreed: whether the practice should apply uniformly to every asymptomatic IPF patient on a legacy antacid prescription, or be decided case by case — the first pulmonologist favors a uniform chart-review sweep; the clinical pharmacologist is only confident in F.O.'s specific case, where the absence of any reflux diagnosis makes the decision unusually clean.